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Abstract
Osteonecrosis of the jaw is a very severe complication in patients using antiresorptive 
drugs, which have been widely applied for the last 10 years. It has prompted an increase 
in number of negative complications such as significantly restricted food intake, reduced 
quality of life with a negative impact on the general health status of the patient as a 
whole. The negative influence of antiresorptive drugs on jaw bones is still not precisely 
known and is the subject of research. More than 30% of patients with rheumatic diseases 
develop osteonecrotic lesions in the jaws due to a relation with bisphosphonates, cor-
ticosteroids or other antiangiogenic treatment administered orally or parenterally. The 
treatment is often protracted, variable and very complicated. The clinical symptoms and 
treatment possibilities are presented, and, based on the clinical results, compared with 
many investigative researches and multicenter studies all over the world. Preventive 
measures are often consistent with other studies, where precautions such as radical den-
tal treatment were observed, especially before antiresorptive treatment initiation. Despite 
the clinical results, which widely differ, the best way to prevent the osteonecrosis of the 
jaw is a necessary interdisciplinary approach and further research.
Keywords: osteonecrosis of the jaw, antiresorptive drugs, interdisciplinary approach, 
quality of life, rheumatic diseases
1. Introduction
Medication-related osteonecrosis of the jaw (MRONJ) was first described in patients with 
multiple myeloma treated with intravenously administered bisphosphonates in 2003. At the 
time, the disease was classified as bisphosphonate-related osteonecrosis of the jaw (BRONJ). 
However, 15 years of development in diagnosing, treating and monitoring the course of the 
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disease revealed the correlation with drugs other than the bisphosphonates. The American 
Association of Maxillofacial Surgeons (AAOMS) standardized the diagnostic criteria for 
BRONJ in 2009, and updated the disease to MRONJ, eventually merging both diseases in 
2014 [1].
Recently, there have been a growing number of cases with osteonecrosis of the jaw diagnosed 
in patients treated with cytostatics, hormonal preparations combined with corticosteroids 
and human monoclonal antibodies. This group of drugs is known as antiresorptive medica-
ments (ARM), with proven cytotoxic effect on mucous membrane of the oral cavity. Most 
often, however, following an invasive procedure in oral cavity that breaches its integrity and 
exposes the alveolar bone, while simultaneously failing to implement measures that promote 
wound healing, they lead to a necrosis. Osteonecrosis of the jaw is confirmed by the clinical 
picture of non-healing post-extraction wound (or dental trauma), which has not healed in 
8 months without medical history of radiation therapy in head and neck region, edema, loose 
teeth, foetor ex ore, fistulas and, in advanced stages, pain.
It is possible to locate the affected area by employing the modern methods such as MRI, CBCT 
or through bone resorption biomarker findings. These diagnostic methods aid in determining 
the stage of the disease and subsequent method of treatment. The treatment is difficult and 
often ineffective, with recurrent complications. When the preventive measures are observed 
and the disease is diagnosed early, followed up by an adequate treatment, the disease can be 
cured, or at least in certain cases, the symptoms in the oral cavity can be alleviated. In the major-
ity of cases, however, MRONJ patients who have been treated with antiresorptive drugs tend to 
also suffer from breast cancer, prostate cancer or multiple myeloma (Figures 1 and 2). We also 
encounter increasing number of patients with osteoporosis and rheumatoid arthritis [2]. Most 
cases of MRONJ arise after prolonged intravenous use of nitrogen-containing bisphospho-
nates. Orally administered nitrogen-containing bisphosphonates cause MRONJ less often [3].
The scope and course of the disease depends on the correlation between other drugs and the 
patient’s overall health status. Antiresorptive treatment is a common treatment method, only 
excluding patients with cancer, rheumatoid arthritis, osteoporosis or the so-called skeletal-related 
Figure 1. The basis of disease in men.
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events (SREs). This term refers collectively to specific serious complications relating to the meta-
static bone disease. SREs include pathological fractures of vertebrae and long bones, malignant 
spinal cord compression, hypercalcemia and cases requiring orthopedic and analgesic radio-
therapy. This treatment improves the quality of life for such patients, and provides them with 
longer lifespan, with minimal undesirable effects.
2. Etiopathogenesis
There are a number of theories concerning the cause of this complication. They are mostly 
related to the formation of necrotic bone caused by the inhibition of bone remodeling with 
bisphosphonates and an antiangiogenic therapy. However, several studies on the develop-
ment of the disease indicate that the bone remodeling inhibition itself cannot cause bone 
exposure. It is necessary for local risk factors to also be present.
The most significant theories about the possible cause are based on the following arguments:
1. The only barrier between the bone and the mouth is a thin mucosa that is easily damaged 
by mechanical irritation (chewing, prosthesis-related trauma).
2. Oral cavity contains a diverse microbial flora that may induce pulpo-periodontal diseases, 
when the area becomes pathologic.
3. A surgical procedure in the area exposes the alveolar bone to a high concentration of 
bacteria.
4. Bone remodeling rate of the jaw and mandible is very high, which leads to a greater ac-
cumulation of bisphosphonates in the mineralized bone tissue [4].
According to a theory, keratinocytes undergo bisphosphonate-induced apoptosis resulting 
in diminished mucous barrier in the oral cavity, which plays a role in the development of 
MRONJ. If an infection in the oral cavity is caused by the naturally occurring post-surgery 
Figure 2. The basis of disease in women.
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bacteria (Actinomyces israelii, Escherichia coli), they will cause the drop in the wound area pH, 
and will release bisphosphonates and calcium salts. The hypothesis is that high concentra-
tions of bisphosphonates increase apoptosis of keratinocytes in the attached gingiva and con-
sequently, allow the penetration of bacteria into deeper tissues. This hypothesis may explain 
why MRONJ occurs only in maxilla and mandible, but not in other bones of the skeleton.
Another theory considers the unique role of bone remodeling rate. Both maxilla and mandible 
are examples of a bone that is subject to an increased bone remodeling, mainly in the alveolar 
socket area and periodontal area, as a result of intensive mechanical stress acting on teeth dur-
ing chewing and other movements of the teeth. It turns out that the bone turnover is constant 
during the life of an individual, regardless of their age [5].
The suppression of remodeling and decrease of bone turnover results from bisphosphonates 
directly affect osteoclasts and their function. Studies examining osteogenesis imperfecta in 
kids reveal that bisphosphonates do not always reduce the level of osteoclasts, but contrary 
to that, under certain conditions, they tend to increase their levels [6, 7]. Suppression of bone 
remodeling could therefore occur through other mechanisms such as intravenous bisphos-
phonate application.
Longitudinal animal studies with long-term application of bisphosphonates revealed 
increased number of multilocular phosphatase-positive cells in jaw and long bones. On the 
surface of the bone, however, the number of osteoclasts is decreased, while the number of 
osteoclasts in the woven bone is increased [8]. A traumatized alveolar compact bone with 
damaged periosteal and endosteal covering and diminished osteoprogenitor cells will acti-
vate osteoclasts and start the bone remodeling process. However, osteoclasts are unable to 
bind themselves to the bone surface and resorp the bone matrix as a result of incorporated 
bisphosphonates. Traumatized bone can hold the attempted osteoclast activation signal, and 
the osteoclasts then accumulate near the bone surface. The purpose of these accumulated 
unconnected osteoclasts in bone tissue is currently unclear [9].
2.1. Infectious agents
The oral cavity is colonized by a number of microorganisms that may become pathogenic 
even after the slightest superficial trauma to the oral mucosa, which then acts as a gateway 
for jaw bone infection. An organism treated with ARM has altered immune response and is 
unable to react efficiently against infectious agents and curb the spread of infection to sur-
rounding tissues of the oral cavity and alveolar processes.
Various in vivo studies on rats describe a link between the periodontal infection and the 
osteonecrosis development. Young adult rats have been administered bisphosphonates for 
15 weeks and had a circumdental wire applied to the first molar for 3 weTeks to induce an 
aggressive periodontitis. Osteonecrosis of the jaw diagnosed in this study had the identical 
course and histological finding to the human manifestations of the disease, with bone seques-
tration, numerous empty osteocyte lacunas and an expression of inflammation. Culture results 
proved that Fusobacterium nucleatum were present. After the subsequent ATB application, 
the signs of osteonecrosis have subsided; however, the healing ad integrum did not happen.
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Numerous similar longitudinal studies confirm the significant role of infectious agents in 
the oral cavity with expressed osteonecrosis [10]. Surgical procedures conducted during a 
bisphosphonate therapy or a periodontal pathology indicating bone remodeling of the alve-
olar bone make it easier for bisphosphonates to accumulate in maxilla or mandible. After 
bisphosphonates in a bone reach the critical concentration, a trigger (tooth extraction) acti-
vates the bone remodeling, simultaneously releasing local deposits of bisphosphonates that 
inhibit the bone healing process. Necrotic osteomyelitis is induced by the slowed-down repair 
process, accompanied by a bone wound contamination by the Actinomyces bacteria.
Hence, efficient debridement, application of antimicrobial mouthwash and application of ATB 
directly on the bone defect and the wound play a very important role in the treatment of ONJ.
3. Clinical picture
In the past, osteonecrosis of the jaw proved to be a serious problem not only in the view of 
possible treatments, but also in the view of the diagnosis itself. Such lesions and conditions 
were usually considered to be osteitis, osteomyelitis or alveolitis, which were thought to have 
been the result of a preceding extraction.
Complications in the oral cavity in patients with MRONJ are usually diverse. The complications 
may emerge due to the progression of the disease, or as a result of medical procedures, which 
produce functional problems such as diminished chewing function, loss of teeth and limited reha-
bilitation of the chewing function. In addition, aesthetic obstructions may also emerge due to the 
loss of teeth, facial contour defects (owing to partial bone resections) or due to enduring oroantral 
fistulas. Patients experience sore mouth, impaired wound healing and drug-induced mucositis.
The most common clinical sign of MRONJ (up to 93.9%) is an exposed necrotic bone. The scope of 
bone exposure may vary greatly and is directly connected neither with the scope of the necrosis 
nor with the severity of the disease. Signs of infection such as swelling of soft tissues, intra/extra 
oral purulent discharge or abscesses may also be present. Patients may suffer from severe pain 
if the infection breaks out of the necrotic tissue, although this symptom is not a requirement—
many patients do not report any pain. In severe cases, local infection may develop into abscesses 
in the deeper areas of the head and neck, resulting in life-threatening conditions. It may even lead 
to an abscess in brain tissues. Some rare cases of septic systemic infection have been documented.
Rare, although typical, symptom of MRONJ is the paresis of alveolar nerve, also known as the 
Vincent’s symptom. It is interesting that it manifests itself in the earlier and in the advanced 
stages of MRONJ. Reduced sensitivity of nervus alveolaris inferior can also be a sign of meta-
static infiltration. Histologic examination is recommended. Other symptoms associated with 
MRONJ include loss of teeth due to structural changes within the necrotic bone and bad 
breath due to bacterial inflammation.
Loss of teeth is the result of a progress of the necrotic damage to the alveolar bone. Bad 
breath as a symptom commonly occurs in patients suffering from MRONJ based on previous 
changes within the necrotic bone and the surrounding soft tissues. This can also be the result 
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of a bacterial colonization of the affected area, usually combined with a non-sterile infec-
tion of the bone and the surrounding soft tissue. This symptom occurs in 71–84% of MRONJ 
patients with periodontitis which form an inflammatory periodontal disease. Polymicrobial 
biofilm swab samples from oral cavity reveal specific bacteria such as Porphyromonas gingi-
valis, Treponema denticola, Tannerella forsythia or Aggregatibacter actinomycetemcomitans.
Thanks to the adequate and effective management of these diseases and their various possible 
stages, it is now possible to correctly diagnose the patient and consequently, try and treat them. 
Though, the treatment itself usually does not bring neither adequate nor successful results, 
which is the reason why such an amount of studies and in vivo and in vitro experiments exist. 
The status of oral cavity in patients undergoing intravenous bisphosphonate therapy after pri-
mary prevention can be maintained to such an extent that the cancer treatment may continue 
without any negative impact on the quality of life of the patient, even when osteonecrotic 
defects and lesions are present. Figures 3 and 4 describe the clinical picture of ONJ.
Figure 4. Osteonecrosis of the left maxilla.
Figure 3. Osteonecrosis of the right mandible.
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4. Prevention
Considering how complex the bisphosphonate-related osteonecrosis of the jaw therapy is, 
primary prevention may be the most important strategic approach to this complication.
Preventive measures are able to reduce, albeit not eliminate, the risk of formation of lesions. 
The rationale behind the primary prevention is the elimination of all focuses of infection in the 
jaw and total denture restoration lege artis.
The radical form of the therapy is comparable to denture restoration in patients before a 
radiation therapy in the head and neck region. All dentists should be familiar with the form 
of the therapy. Every patient should be subject to dental examination and panoramic dental 
X-ray before their planned antiresorptive therapy (Figure 5). In case surgical procedures 
in oral cavity (usually teeth extractions) are necessary as a part of the denture restoration 
procedure, it is recommended, if possible, to postpone the launch of ARM treatment by 
2–3 weeks, or, preferably, until clear signs of bone healing show up on the skiagram. Other 
dental examinations and good oral hygiene are, of course, essential in the course of the ARM 
treatment.
In cancer patients taking intravenous bisphosphonates, the most conservative therapy 
possible is indicated for dental diseases. All invasive procedures involving jaw bones are 
strictly contraindicated (tooth extractions, periodontal-dentoalveolar surgery, implantol-
ogy). It is recommended to refer the patients for whom these procedures are necessary 
to a specialized department of maxillofacial surgery. Such preventive measures are rec-
ommended to be followed not only in cancer patients who are subject to bisphosphonate 
treatment, but also in patients who use other drugs affecting bone metabolism or osteoclast 
function inhibitors.
Figure 5. Panoramic X-ray with osteonecrosis of the right mandible.
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The secondary prevention, in terms of ARM treatment interruption—the so-called drug 
holiday—is bit problematic. So far, there is no scientific evidence that the interruption of a 
therapy prior to surgery in the oral cavity reduced the risk of developing osteonecrosis of 
the jaw. According to AAOMS, suspending intravenous bisphosphonates has no significant 
short-term benefit in case the lesions are already present. Long-term treatment suspension, 
however, may stabilize the affected area, alleviate the clinical signs and also reduce the risk 
of new sites being affected. The priority still lies in the treatment of malignant diseases, and 
therefore, the suspension of bisphosphonates has to be thoroughly assessed.
The situation with monoclonal antibodies is different. Based on current knowledge about 
the effect of denosumab on bone remodeling, it is recommended to suspend the drug prior 
to any planned surgery in the oral cavity, in order to reduce the risk of developing osteone-
crosis of the jaw. Suspending denosumab treatment seems to be appropriate, even in cases 
of an already developed osteonecrosis of the jaw, which can lead to heightened healing of 
the lesion. Some authors recommend suspending bevacizumab 6–8 weeks before surgery 
and resuming the medication 4 weeks after the procedure to prevent complications with 
wound healing.
5. Treatment
The primary goal of the treatment is to minimize the occurrence of MRONJ. Even though 
cases of spontaneous formation of MRONJ do exist, the majority of cases develop after a 
surgery.
In the first place, it is necessary to carry out a preservation treatment and consequent pros-
thetic and surgical treatment lege artis. This includes restorations of carious teeth, repairing 
of overhanging fillings, or extracting devitalized or destroyed teeth with extensive periapical 
findings. ARM treatment should initiate or resume only after the extraction wound in the 
socket has healed thoroughly. Prevention is important in terms of maintaining the functional-
ity of healthy teeth.
Examination of the affected mucosa is necessary in patients with prosthetic replacement, since 
decubiti, traumatic lesions or fissural granuloma may emerge in the area. For these reasons, 
temporary restoration is contraindicated in many cases. Dentoalveolar procedure must be 
carried out in the gentlest manner, preferably at a maxillofacial surgery facility. It is necessary 
to inform the patient about the possible risks. Chlorhexidine mouth washes are indicated both 
before and after the dentoalveolar procedure. The surgery is performed under the influence of 
antibiotics, which continue to be employed after the procedure.
MRONJ treatment is very demanding in terms of time; therefore, AAOMS recommends a con-
servative approach, in an attempt to delay the surgical resection treatment, which is indicated 
in the advanced stages of the disease. Palliative conservative treatment is usually applied, 
since only a small percentage of patients will experience complete healing ad integrum. The 
conservative approach consists of equalization of sharp bone edges, sequestrectomy, necrotic 
area teeth extractions, and incisions and drainages under total antibiotic and topical treatment.
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Surgical treatment consists of complete removal of the necrotic foci, which serve as a fertile 
ground for infection, followed by wound closure with soft tissue that is finely vascularized, 
using layered suture. During the radical surgical resection, there are still concerns about the 
resulting wounds, difficulty in healing and progression of osteonecrotic foci.
Several studies point to the possibility of employing new treatment methods such as PRP, ozone 
or hyperbaric oxygen therapies. The benefit for cancer patients who are undergoing intravenous 
bisphosphonate treatment is bone pain relief and retreat of other bone complications. The basic 
rule is to preserve the quality of life for these patients, which includes a thorough oral health 
care, patient education, regular visits to the dentist, pain management and reports on health 
status, edemas, pain or bone exposure. It is also important to prevent the spread of new necrotic 
sockets by observing the proper prevention. Staging and management is described in Table 1.
Patients with aforementioned drugs in their medical history need to be treated as risk patients 
in view of invasive procedures in the oral cavity. Currently, the majority of osteonecrosis are of 
iatrogenic nature, caused by the incorrect choice of treatment for risk patients by the  medical 
Table 1. Staging and management.
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staff. The cause of this unfavorable situation lies in the lack of communication between the 
specialist prescribing the high-risk drug and the treating dentist. The lack of awareness of the 
issue, both in patients and treating dentists, also plays its role. Medical specialist prescribing 
a high-risk drug is obligated to inform the patient about the risks and adverse effects of the 
planned treatment and to remind them to specifically inform their dentist about this fact. By 
disregarding this obligation on the part of the specialist (clinical oncologist, internist, rheu-
matologist, urologist, gynecologist, endocrinologist, orthopedist, etc.), the patient usually has 
no idea about the risk involved; however, the development of iatrogenic osteonecrosis may be 
prevented by the right approach by the treating dentist. They should not underestimate drug 
anamnesis prior to any invasive procedure in the oral cavity. Precise and targeted medical 
history can help identify at-risk patients and to choose the right treatment plan.
The incidence of MRONJ can be divided into two groups: patients with non-oncological dis-
ease (osteoporosis, rheumatoid arthritis) and patients with cancer who take high doses of 
intravenous bisphosphonates.
In the second group, the incidence after 36 months of treatment ranges from 1 to 12%. The 
majority of cases described are connected with the use of zoledronate and pamidronate in 
treatment of multiple myeloma and bone metastases. So far, the results and recommendations 
on potential treatment for these conditions refer to the multicenter studies conducted in the 
last 15 years.
The study named DEFEND (Denosumab Evaluation for Preserving Bone Density) was a 
double-blind, multicenter, placebo-controlled, third phase study on 332 postmenopausal 
women with osteopenia and respective T-scores in the range of 1.5–2.5 SD. Denosumab was 
applied in 6-month intervals at a dose of 60 mg subcut, in contrast to placebo. Both groups of 
patients took a calcium supplement (100 mg a day) and vitamin D. The primary objective was 
to observe the lumbar spine bone mineral density after 24 months of treatment.
The results of the study showed that, compared with placebo, denosumab significantly 
increased the value of BMD in lumbar spine (by 6.5%). Denosumab also increased the density 
in the proximal part of femur (3.4%) and in the distal end of radius (by 1.4%). In the placebo 
group, the BMD decreased in these areas.
In another study, titled DECIDE (Determining Efficacy: Comparison of Initiating Denosumab 
vs. Alendronate), the effectiveness of denosumab with the same dosage as in the study 
DEFEND was compared to alendronic acid with a dosage of 70 mg, once a week, in order to 
reduce the risk of osteoporotic fractures. The yearlong study enrolled 1189 postmenopausal, 
relatively older women with more serious osteopenia than in the DEFEND, with half the 
women having a fracture in their medical history. Calcium and vitamin D supplementation 
has been the norm throughout the study. The primary measured indicator was the change 
in the density of proximal femur. Moreover, bone densities of lumbar spine, femoral neck, 
trochanter and distal radius were also monitored.
The results showed that denosumab improved bone density in all the monitored areas mark-
edly better than alendronic acid, as early as at the end of the first month. At the same time, 
resorption markers significantly decreased in the group treated with denosumab, compared 
to the alendronic acid group.
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Large, randomized, placebo-controlled study called FREEDOM (Fracture Reduction Eval-
uation of Denosumab in Osteoporosis Every 6 Months) studied the reduction of incidence of 
osteoporotic fractures. The authors monitored 7868 women aged 60–90, with an average BMD 
T-score of −2.5, but not lower than −4.0.
After 3 years, the incidence of new vertebral fractures identified on X-rays in women treated 
with denosumab was 2.3%, while the incidence in the control group was 7.2%. The treatment 
reduced the relative risk of vertebral fractures by 68%. The cumulative incidence of hip frac-
tures was 0.7% in the treatment group and 1.2% in the control group (40% reduction in the 
risk of fractures). There were no recorded significant differences in incidence of side effects 
such as cardiovascular complications, infections, fracture healing time and hypercalcemia 
between the treated and the control group [11].
An important outcome of these studies was the discovery that denosumab significantly 
increases bone density, even in areas with prevalence of cortical bones. From these results, it 
can be concluded that alendronate has the longest half-life decay (10 years), while denosumab 
has a reversible effect because it does not deposit into bone tissue.
5.1. Combining antiresorptive drugs and hormonal therapy
Several studies refer to clinical cases of patients with antiresorptive drug-related osteone-
crosis of the jaw that describe improvement in local findings and bone remodeling and an 
increase in patient’s quality of life after switching bisphosphonates for hormonal therapy 
with recombinant parathyroid hormone teriparatide [12, 13].
Teriparatide was approved for the treatment of postmenopausal osteoporosis. Unlike the anti-
resorptive treatment, teriparatide has anabolic effect in bone which stimulates bone remodel-
ing and bone tissue density. Intermittent administration (once a day) leads to a temporary 
increase of serum concentrations and preferential stimulation of the osteoblast activity, which 
leads to bone formation stimulation. The effect lies in the increase of bone mass and the num-
ber of osteoblasts, and the consequent strength of bones.
Some clinical trials document a positive effect of teriparatide and parathyroid hormone which 
reduces the risk of vertebral fractures while increasing the bone mineral density (BMD). The 
preparation is administered subcutaneously, one injection a day. Recommended treatment 
duration is 18 months. Side effects include cephalalgia, nausea and hypercalcemia. After its 
administration, osteal healing in mouth cavity was documented.
According to the trial results, hormonal preparations used after stimulating the activity of 
osteoblast and osteoclasts could be employed in the treatment of non-oncological osteonecro-
sis. However, current trials are very small, and there is no sufficient evidence, which calls for 
more studies. Treatment is difficult, and it is therefore available only for some patients.
Teriparatide should not be used in cancer patients due to an increased risk of osteosarco-
mas, which were found in preclinical trials on rats. The teriparatide therapy should not be 
indicated in patients who inject their bisphosphonates, zoledronic acid or pamidronic acid 
because of the increased incidence of necrosis and associated severe complications, in contrast 
to orally administered bisphosphonates.
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6. Conclusion
The aforementioned clinical recommendations are based on relevant data, scientific evidence, 
available literature and the empirical experience of the authors. Despite the effort, neither 
standard nor recommended procedure may still be defined.
Clinical recommendation and subsequent treatment should be assessed by the treating phy-
sician based on the patient’s status and their needs and preferences, which should alleviate 
their difficulties and improve the quality of life of the patient suffering from the osteonecrosis 
of the jaw. Compliance with preventive measures before and during the antiresorptive treat-
ment seems beneficial; however, it is also considerably complicated.
The ARM-induced osteonecrosis of the jaw poses a current problem with a number of yet unan-
swered questions. In general, it is believed that the cause of the osteonecrosis is multifactorial, 
dependent not only on administered preparations, but also on the underlying oncological dis-
ease, type of chemotherapy, hormonal treatment, associated illnesses, age and addiction case 
history. It is therefore necessary to correctly set up and indicate the pharmacological and surgical 
treatment, monitor the bone antiresorptive therapy, with focus on prevention and complications.
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